齐拉西酮与氯丙嗪治疗72例首发精神分裂症对照研究

目的:评价齐拉西酮治疗首发精神分裂症的疗效及安全性。方法:将72例首发精神分裂症患者随机分为研究组36例,口服齐拉西酮治疗;对照组36例,口服氯丙嗪治疗。观察8周,于治疗前及治疗第1、2、4、8周末采用阳性与阴性症状量表、不良反应量表评价临床疗效与不良反应。结果:治疗8周末研究组总有效率88.9%,对照组为86.1%(P>0.05)。两组阳性与阴性症状量表总分及各因子分均较治疗前有显著性下降(P<0.05或P<0.01)。研究组阴性症状分较对照组下降更为显著(P<0.05),研究组锥体外系反应发生率显著低于对照组(P<0.05)。结论:齐拉西酮治疗首发精神分裂症疗效与氯丙嗪相当,但改善阴性症状效果更为显著,锥体外系不良反应显著较少,起效快,安全性更高,服药依从性好。

A control study of ziprasidone vs.chlorpromazine in the treatment of first-episode schizophrenia

Objective:To explore the clinical efficacy and safety of ziprasidone in the treatment of first-episode schizophrenia.Methods:72 fitst-episode schizophrenis were randomly divided into reaearch group(n=36)took orally ziprasidone and contral group(n=36)doing chlorpromazine for 8 weeks.clinical efficacies were assessed with the positive and Negative Syndrome Scale(PANSS) and adverse reactions with the Treatment Emergent Symptom Scal(TESS).before treatment and at the end of the 1st,2nd,4th and 8th week.Results: At the end of the 8th week,total effective rates were 88.9% in the research and 88.1% in the control group respectively(P>0.05);the total and all factor scores of the PANSS of both groups lowered more significantly compared with pretreatment(P<0.05or<0.01);scores of negative symptoms lowere more significantly in the research than in the control group(P<0.05);EPS rate of adverse reaction was significantly lower in the research than in the control group(P<0.05).Conclusions: Ziprasidone has evident effect equivalent to chlorpromazine,improves the negative symptoms more significantly and has lower EPS rale of adverse reaction,take efects faster,and has highter safety and better compliance.